Serine/Threonine Protein Kinase A Raf ? Pipeline Review, H1?2018

Posted by Vansh Rao on February 7th, 2018

Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Serine/threonineprotein kinase ARaf is an enzyme that in humans is encoded by the ARAF gene. It is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It regulates the TOR signaling cascade.

Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 2 and 2 respectively. Report covers products from therapy areas Oncology which include indications Metastatic Melanoma, NonSmall Cell Lung Cancer, Solid Tumor and Colorectal Cancer.

The latest report SerineThreonine Protein Kinase A Raf Pipeline Review, H1 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1
The report reviews Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics

For more information, please visit @ https://www.24marketreports.com/life-sciences/serinethreonine-protein-kinase-a-raf-proto-oncogene-a-raf-or-proto-oncogene-pks-or-araf-or-ec-27111pipeline-review-h1-2018-market-98

Table Of Content-

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Overview
Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd

Contact Us-
 New York City Zone 01,
 United States,
 Int’l: (+1) 646 781 7170,
 UK(Toll free): +44 800 088 5734,
 help@24marketreports.com